A Phase 3 interventional study of Evolocumab and Placebo in Coronary Heart Disease (CHD), sponsored by Amgen. Completed at 852 sites in 33 countries. Open to participants aged 50 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-06-25.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 274 studies in Coronary Disease with a site in United States — 12 open to participants now, 23 under way, 2 of them phase 3. Coronary Disease · United States.
Among the 274 studies in Coronary Disease with a site in United States, this one is the 6th largest by enrollment of the 184 interventional ones that give a count, is one of 9 that started in 2019, is one of 35 in phase 3, and was the 242nd registered.
1,521 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.
Browse Coronary Disease studies →12 of the 274 studies in Coronary Disease with a site in United States are open now. Recruiting first, the newest first:
Teleflex · Sites in United States, France, Latvia and 1 more country
Ages 18–80
Amgen · Sites in United States, Australia, Canada and 1 more country
Ages 50–105
West Virginia School of Osteopathic Medicine · Sites in United States
Ages 18–64
University of California, Los Angeles · Sites in United States
Ages 60–80
Weill Medical College of Cornell University · Sites in United States, Austria, Canada and 3 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 105 Coronary Disease studies recruiting now, 63 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 50 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
274 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 43 · Phase 3 36 · Phase 4 18
First in 1973; this study’s year is marked. 9 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12,301 is above the median of 160 across 779 interventional studies indexed under Coronary Disease.
Median enrollment 200 across the 184 interventional studies, 324 across the 87 observational. Of the 235 that completed or were terminated, 88 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
92 of 274 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Amgen has 3 studies filed under Coronary Disease — fewer than ten, so there is no comparison to draw.
10 of the studies in Coronary Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05997693Phase 3Weill Medical College of Cornell UniversityOne-Month DAPT in CABG Patients | 2027-01 |
| NCT02694094Johns Hopkins UniversityImpact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy | 2026-12 |
| NCT06170541Johns Hopkins UniversityCORE-COMPARE Pilot Study | 2026-12 |
| NCT05918380University Hospitals Cleveland Medical CenterProject 3: ACHIEVE- CHD | 2027-01-01 |
| NCT00406185Intermountain Health Care, Inc.Database Registry of the Intermountain Heart Collaborative Study | 2027-03 |
Add all 10 to your calendar (.ics) → With an account.
Among the 274 studies in Coronary Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a cardiovascular event.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Lipid Criteria: Low-density lipoprotein cholesterol (LDL-C) ≥ 90 mg/dL (≥ 2.3 mmol/L) or non high-density lipoprotein cholesterol (non-HDL)-C ≥ 120 mg/dL (≥ 3.1 mmol/L), or apolipoprotein B ≥ 80 mg/dL (≥ 1.56 µmol/L).
3.Diagnostic evidence of at least one of the following (A-D) at screening:
A.Significant coronary artery disease (CAD) meeting at least 1 of the following criteria:
History of coronary revascularization with multi-vessel coronary disease as evidenced by any of the following:
B. Significant atherosclerotic cerebrovascular disease meeting at least 1 of the following criteria:
C. Significant peripheral arterial disease meeting at least 1 of the following criteria:
D. Diabetes mellitus with at least 1 of the following:
diabetes diagnosis ≥10 years ago.
•At least 1 of the following 1 high-risk criteria (most recent lab values within 6 months prior to screening, as applicable):
Current tobacco use.
-≥65 years of age.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive placebo subcutaneous injection once every 2 weeks (Q2W).
Drug: Placebo
Participants will receive 140 mg evolocumab by subcutaneous injection Q2W.
Drug: Evolocumab
Administered subcutaneously using an autoinjector pen.
Also known as: AMG 145, Repatha
Administered subcutaneously using an autoinjector pen.
Number of Participants Who Experienced Coronary Heart Disease (CHD) Death, Myocardial Infarction (MI), or Ischemic Stroke, Whichever Occurred First
All deaths and individual components were adjudicated by an independent external clinical events committee (CEC), using standardized definitions. The number of participants who experienced CHD death, MI, or ischemic stroke, whichever occurred first, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.
Time frame: From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months
Number of Participants Who Experienced CHD Death, MI, Ischemic Stroke, or Any Ischemia-driven Arterial Revascularization, Whichever Occurred First
All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced CHD death, MI, ischemic stroke, or any ischemia-driven arterial revascularization, whichever occurred first, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.
Time frame: From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months
Number of Participants Who Experienced MI, Ischemic Stroke, or Any Ischemia-driven Arterial Revascularization
All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced MI, ischemic stroke, or any ischemia-driven arterial revascularization, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.
Time frame: From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months
Number of Participants Who Experienced CHD Death, MI, or Any Ischemia-driven Arterial Revascularization
All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced CHD death, MI, or any ischemia-driven arterial revascularization, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.
Time frame: From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months
Number of Participants Who Experienced Cardiovascular Death, MI, or Ischemic Stroke
All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced cardiovascular death, MI, or ischemic stroke, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.
Time frame: From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months
Number of Participants Who Experienced CHD Death or MI
All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced CHD death or MI, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.
Time frame: From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months
Number of Participants Who Experienced MI
All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced MI, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.
Time frame: From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months
Number of Participants Who Experienced Any Ischemia-driven Arterial Revascularization
All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced ischemia-driven arterial revascularization, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.
Time frame: From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months
Number of Participants Who Experienced CHD Death
All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced CHD death, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.
Time frame: From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months
Number of Participants Who Experienced Cardiovascular Death
All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced cardiovascular death, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.
Time frame: From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months
Number of Participants Who Died Due to Any Cause
All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who died due to any cause, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.
Time frame: From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months
Number of Participants Who Experienced Ischemic Stroke
All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced ischemic stroke, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.
Time frame: From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months
Participants were enrolled at 745 research centers in North America, Europe, Asia Pacific, and Latin America between June 2019 and July 2025.
| Milestone | Placebo Q2W | Evolocumab 140 mg Q2W |
|---|---|---|
| Started | 6128 | 6129 |
| Completed | 5985 | 5999 |
| Not completed | 143 | 130 |
| Withdrew: Withdrawal of consent from trial | 104 | 93 |
| Withdrew: Lost to follow-up | 24 | 19 |
| Withdrew: Administrative reasons | 15 | 16 |
| Withdrew: Various reasons | 0 | 2 |
All deaths and individual components were adjudicated by an independent external clinical events committee (CEC), using standardized definitions. The number of participants who experienced CHD death, MI, or ischemic stroke, whichever occurred first, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.
| Participants | Placebo Q2W | Evolocumab 140 mg Q2W |
|---|---|---|
| Number of Participants Who Experienced Coronary Heart Disease (CHD) Death, Myocardial Infarction (MI), or Ischemic Stroke, Whichever Occurred First | 443 | 336 |
All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced CHD death, MI, ischemic stroke, or any ischemia-driven arterial revascularization, whichever occurred first, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.
| Participants | Placebo Q2W | Evolocumab 140 mg Q2W |
|---|---|---|
| Number of Participants Who Experienced CHD Death, MI, Ischemic Stroke, or Any Ischemia-driven Arterial Revascularization, Whichever Occurred First | 907 | 747 |
All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced MI, ischemic stroke, or any ischemia-driven arterial revascularization, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.
| Participants | Placebo Q2W | Evolocumab 140 mg Q2W |
|---|---|---|
| Number of Participants Who Experienced MI, Ischemic Stroke, or Any Ischemia-driven Arterial Revascularization | 834 | 674 |
All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced CHD death, MI, or any ischemia-driven arterial revascularization, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.
| Participants | Placebo Q2W | Evolocumab 140 mg Q2W |
|---|---|---|
| Number of Participants Who Experienced CHD Death, MI, or Any Ischemia-driven Arterial Revascularization | 819 | 664 |
All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced cardiovascular death, MI, or ischemic stroke, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.
| Participants | Placebo Q2W | Evolocumab 140 mg Q2W |
|---|---|---|
| Number of Participants Who Experienced Cardiovascular Death, MI, or Ischemic Stroke | 503 | 374 |
All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced CHD death or MI, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.
| Participants | Placebo Q2W | Evolocumab 140 mg Q2W |
|---|---|---|
| Number of Participants Who Experienced CHD Death or MI | 313 | 232 |
All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced MI, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.
| Participants | Placebo Q2W | Evolocumab 140 mg Q2W |
|---|---|---|
| Number of Participants Who Experienced MI | 229 | 149 |
All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced ischemia-driven arterial revascularization, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.
| Participants | Placebo Q2W | Evolocumab 140 mg Q2W |
|---|---|---|
| Number of Participants Who Experienced Any Ischemia-driven Arterial Revascularization | 699 | 561 |
All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced CHD death, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.
| Participants | Placebo Q2W | Evolocumab 140 mg Q2W |
|---|---|---|
| Number of Participants Who Experienced CHD Death | 117 | 105 |
All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced cardiovascular death, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.
| Participants | Placebo Q2W | Evolocumab 140 mg Q2W |
|---|---|---|
| Number of Participants Who Experienced Cardiovascular Death | 195 | 156 |
All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who died due to any cause, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.
| Participants | Placebo Q2W | Evolocumab 140 mg Q2W |
|---|---|---|
| Number of Participants Who Died Due to Any Cause | 539 | 434 |
All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced ischemic stroke, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.
| Participants | Placebo Q2W | Evolocumab 140 mg Q2W |
|---|---|---|
| Number of Participants Who Experienced Ischemic Stroke | 144 | 115 |
Collected over All-cause mortality: From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months. Serious adverse events (AEs) and other AEs: From first dose of trial drug to last dose + 30 days or end of trial; median (min, max) time on trial was 51.5 (0.0, 72.4) months.. Non-serious events are listed at a 0.1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Q2W | 539/6,128 (8.8%) | 1,772/6,122 (28.9%) | 35/6,122 (0.6%) |
| Evolocumab 140 mg Q2W | 434/6,129 (7.1%) | 1,726/6,125 (28.2%) | 55/6,125 (0.9%) |
| Event | Placebo Q2W | Evolocumab 140 mg Q2W |
|---|---|---|
| Angina unstableCardiac disorders | 96/6122 | 102/6125 |
| Coronary artery diseaseCardiac disorders | 101/6122 | 81/6125 |
| Angina pectorisCardiac disorders | 100/6122 | 83/6125 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 69/6122 | 96/6125 |
| COVID-19 pneumoniaInfections and infestations | 86/6122 | 82/6125 |
| Peripheral arterial occlusive diseaseVascular disorders | 86/6122 | 75/6125 |
| Atrial fibrillationCardiac disorders | 76/6122 | 68/6125 |
| PneumoniaInfections and infestations | 64/6122 | 72/6125 |
| Cardiac failureCardiac disorders | 63/6122 | 43/6125 |
| HypertensionVascular disorders | 41/6122 | 23/6125 |
| Event | Placebo Q2W | Evolocumab 140 mg Q2W |
|---|---|---|
| MyalgiaMusculoskeletal and connective tissue disorders | 18/6122 | 30/6125 |
| HeadacheNervous system disorders | 6/6122 | 11/6125 |
| RashSkin and subcutaneous tissue disorders | 2/6122 | 9/6125 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/6122 | 7/6125 |
| NauseaGastrointestinal disorders | 3/6122 | 8/6125 |
FAS included all randomized participants. All participants were analyzed according to their randomized treatment assignment.
| Age, Continuous(years) | Placebo Q2W | Evolocumab 140 mg Q2W | Total |
|---|---|---|---|
| Mean | 65.3 ± 6.9 | 65.5 ± 6.9 | 65.4 ± 6.9 |
| Sex: Female, Male(Participants) | Placebo Q2W | Evolocumab 140 mg Q2W | Total |
|---|---|---|---|
| Female | 2595 | 2619 | 5214 |
| Male | 3533 | 3510 | 7043 |
| Ethnicity (NIH/OMB)(Participants) | Placebo Q2W | Evolocumab 140 mg Q2W | Total |
|---|---|---|---|
| Hispanic or Latino | 1016 | 1017 | 2033 |
| Not Hispanic or Latino | 5110 | 5110 | 10220 |
| Unknown or Not Reported | 2 | 2 | 4 |
| Race (NIH/OMB)(Participants) | Placebo Q2W | Evolocumab 140 mg Q2W | Total |
|---|---|---|---|
| American Indian or Alaska Native | 28 | 25 | 53 |
| Asian | 243 | 245 | 488 |
| Native Hawaiian or Other Pacific Islander | 2 | 3 | 5 |
| Black or African American | 123 | 115 | 238 |
| White | 5693 | 5708 | 11401 |
| More than one race | 4 | 3 | 7 |
| Unknown or Not Reported | 35 | 30 | 65 |
Showing the first 100 of 852 sites across 33 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) The product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
Data sharing details ↗ · www.amgen.com
Ran from Jun 2019 to primary completion in Jul 2025, 73 months.
Results were first posted in Jun 2026, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab